The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study

Marvin S. Swartz, H. Ryan Wagner, Jeffrey W. Swanson, T. Scott Stroup, Joseph Patrick McEvoy, Fred Reimherr, Del D. Miller, Mark McGee, Ahsan Khan, Jose M. Canive, Sonia M. Davis, John K. Hsiao, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances. Methods: Schizophrenic subjects were recruited at 57 U.S. sites and randomly assigned to olanzapine, perphenazine, quetiapine, risperidone or ziprasidone for up to 18 months. The primary aim of this analysis was to delineate differences between the overall effectiveness of these five treatments among patients who used or did not use illicit substances. Results: There were no significant differences between treatment groups in time to all-cause treatment discontinuation among patients who use illicit drugs (median 3.3 to 6.8 months). Among non-users time to treatment discontinuation was significantly longer for patients treated with olanzapine (median 13.0 months) than perphenazine ( 5.9 months), risperidone (5.6 months), or quetiapine (5.0 months); time to discontinuation for ziprasidone (4.3 months) was even shorter, although the latter difference was not significant. The difference between risperidone and quetiapine, although small, was significant. All remaining differences were non-significant. Similar results were found for discontinuation due to inefficacy. There were no differences between illicit users and non-users in symptom reduction and global improvement, after adjustment for differential duration of treatment. Differences in discontinuation results were attenuated by non-compliance, but the trends persisted after controlling for treatment compliance. Conclusions: Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment.

Original languageEnglish (US)
Pages (from-to)39-52
Number of pages14
JournalSchizophrenia Research
Volume100
Issue number1-3
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

olanzapine
Antipsychotic Agents
Risperidone
Perphenazine
Street Drugs
Substance-Related Disorders
Schizophrenia
Therapeutics
Proxy
Double-Blind Method
Quetiapine Fumarate

Keywords

  • Antipsychotics
  • Dual disorders
  • Schizophrenia
  • Substance abuse

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances : Results from the CATIE study. / Swartz, Marvin S.; Wagner, H. Ryan; Swanson, Jeffrey W.; Stroup, T. Scott; McEvoy, Joseph Patrick; Reimherr, Fred; Miller, Del D.; McGee, Mark; Khan, Ahsan; Canive, Jose M.; Davis, Sonia M.; Hsiao, John K.; Lieberman, Jeffrey A.

In: Schizophrenia Research, Vol. 100, No. 1-3, 01.03.2008, p. 39-52.

Research output: Contribution to journalArticle

Swartz, MS, Wagner, HR, Swanson, JW, Stroup, TS, McEvoy, JP, Reimherr, F, Miller, DD, McGee, M, Khan, A, Canive, JM, Davis, SM, Hsiao, JK & Lieberman, JA 2008, 'The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study', Schizophrenia Research, vol. 100, no. 1-3, pp. 39-52. https://doi.org/10.1016/j.schres.2007.11.034
Swartz, Marvin S. ; Wagner, H. Ryan ; Swanson, Jeffrey W. ; Stroup, T. Scott ; McEvoy, Joseph Patrick ; Reimherr, Fred ; Miller, Del D. ; McGee, Mark ; Khan, Ahsan ; Canive, Jose M. ; Davis, Sonia M. ; Hsiao, John K. ; Lieberman, Jeffrey A. / The effectiveness of antipsychotic medications in patients who use or avoid illicit substances : Results from the CATIE study. In: Schizophrenia Research. 2008 ; Vol. 100, No. 1-3. pp. 39-52.
@article{876ea60616ca40dea94948ba0f5b0cc3,
title = "The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study",
abstract = "Objective: This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances. Methods: Schizophrenic subjects were recruited at 57 U.S. sites and randomly assigned to olanzapine, perphenazine, quetiapine, risperidone or ziprasidone for up to 18 months. The primary aim of this analysis was to delineate differences between the overall effectiveness of these five treatments among patients who used or did not use illicit substances. Results: There were no significant differences between treatment groups in time to all-cause treatment discontinuation among patients who use illicit drugs (median 3.3 to 6.8 months). Among non-users time to treatment discontinuation was significantly longer for patients treated with olanzapine (median 13.0 months) than perphenazine ( 5.9 months), risperidone (5.6 months), or quetiapine (5.0 months); time to discontinuation for ziprasidone (4.3 months) was even shorter, although the latter difference was not significant. The difference between risperidone and quetiapine, although small, was significant. All remaining differences were non-significant. Similar results were found for discontinuation due to inefficacy. There were no differences between illicit users and non-users in symptom reduction and global improvement, after adjustment for differential duration of treatment. Differences in discontinuation results were attenuated by non-compliance, but the trends persisted after controlling for treatment compliance. Conclusions: Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment.",
keywords = "Antipsychotics, Dual disorders, Schizophrenia, Substance abuse",
author = "Swartz, {Marvin S.} and Wagner, {H. Ryan} and Swanson, {Jeffrey W.} and Stroup, {T. Scott} and McEvoy, {Joseph Patrick} and Fred Reimherr and Miller, {Del D.} and Mark McGee and Ahsan Khan and Canive, {Jose M.} and Davis, {Sonia M.} and Hsiao, {John K.} and Lieberman, {Jeffrey A.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1016/j.schres.2007.11.034",
language = "English (US)",
volume = "100",
pages = "39--52",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The effectiveness of antipsychotic medications in patients who use or avoid illicit substances

T2 - Results from the CATIE study

AU - Swartz, Marvin S.

AU - Wagner, H. Ryan

AU - Swanson, Jeffrey W.

AU - Stroup, T. Scott

AU - McEvoy, Joseph Patrick

AU - Reimherr, Fred

AU - Miller, Del D.

AU - McGee, Mark

AU - Khan, Ahsan

AU - Canive, Jose M.

AU - Davis, Sonia M.

AU - Hsiao, John K.

AU - Lieberman, Jeffrey A.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Objective: This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances. Methods: Schizophrenic subjects were recruited at 57 U.S. sites and randomly assigned to olanzapine, perphenazine, quetiapine, risperidone or ziprasidone for up to 18 months. The primary aim of this analysis was to delineate differences between the overall effectiveness of these five treatments among patients who used or did not use illicit substances. Results: There were no significant differences between treatment groups in time to all-cause treatment discontinuation among patients who use illicit drugs (median 3.3 to 6.8 months). Among non-users time to treatment discontinuation was significantly longer for patients treated with olanzapine (median 13.0 months) than perphenazine ( 5.9 months), risperidone (5.6 months), or quetiapine (5.0 months); time to discontinuation for ziprasidone (4.3 months) was even shorter, although the latter difference was not significant. The difference between risperidone and quetiapine, although small, was significant. All remaining differences were non-significant. Similar results were found for discontinuation due to inefficacy. There were no differences between illicit users and non-users in symptom reduction and global improvement, after adjustment for differential duration of treatment. Differences in discontinuation results were attenuated by non-compliance, but the trends persisted after controlling for treatment compliance. Conclusions: Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment.

AB - Objective: This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances. Methods: Schizophrenic subjects were recruited at 57 U.S. sites and randomly assigned to olanzapine, perphenazine, quetiapine, risperidone or ziprasidone for up to 18 months. The primary aim of this analysis was to delineate differences between the overall effectiveness of these five treatments among patients who used or did not use illicit substances. Results: There were no significant differences between treatment groups in time to all-cause treatment discontinuation among patients who use illicit drugs (median 3.3 to 6.8 months). Among non-users time to treatment discontinuation was significantly longer for patients treated with olanzapine (median 13.0 months) than perphenazine ( 5.9 months), risperidone (5.6 months), or quetiapine (5.0 months); time to discontinuation for ziprasidone (4.3 months) was even shorter, although the latter difference was not significant. The difference between risperidone and quetiapine, although small, was significant. All remaining differences were non-significant. Similar results were found for discontinuation due to inefficacy. There were no differences between illicit users and non-users in symptom reduction and global improvement, after adjustment for differential duration of treatment. Differences in discontinuation results were attenuated by non-compliance, but the trends persisted after controlling for treatment compliance. Conclusions: Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment.

KW - Antipsychotics

KW - Dual disorders

KW - Schizophrenia

KW - Substance abuse

UR - http://www.scopus.com/inward/record.url?scp=39949083024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39949083024&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2007.11.034

DO - 10.1016/j.schres.2007.11.034

M3 - Article

C2 - 18191383

AN - SCOPUS:39949083024

VL - 100

SP - 39

EP - 52

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -